Posters

Effects of anti-hypertensive drugs on choroidal thickness in systemic hypertensive patients

Poster Details

First Author: H.Kanar TURKEY

Co Author(s):    A. Arsan   B. Kanar                          

Abstract Details



Purpose:

We aimed to evaluate and compare the effects of anti-hypertensive drugs on choroidal thickness in new diagnosed systemic hypertensive patients.

Setting:

This is a prospective study.

Methods:

In this study comprised 80 new diagnosed hypertensive patients and 80 healthy control subjects. Subfoveal choroidal thickness (SFCT) was measured with spectral-domain optical coherence tomography (SD-OCT) (RS-3000, Nidek). Patients who have never been used anti hypertensive drug before and who have regulated blood pressure (BP) after starting treatment with single drug. 80 patients were divided into 4 groups according to the medication they used and beta receptor blockers (B-blockers), angiotensin-converting enzyme inhibitors (ACEİ), angiotensin II receptor blockers (ARB) and calcium channel blockers (CCB) were used for regulating the BP. SFCT were measured before treatment, at 3th month and at 6th. We compared the SFT values between healty groups and hypertensive gruops and also we compared according to the medication they received.

Results:

Mean age was 43.6 ± 2.4 years in hypertensive subjects and 43.3 ± 2.1 years in the control group (p = 0.92) and there was no statistical difference between the treatment groups and there was no statistical difference between the mean age of the 4 treatment groups within the hypertensive patient group. Initial mean SFCT in hypertensive patients (310,43±42,80µm) was higher than control groups (300,86±38,78µm) but no significant difference in SFCT was evident between patients and controls (P = 0.62). At 3th months evaluation, mean SFCT values decreased in each treatment group but there was no statistical difference. At 6th month, SFCT values were 276,67±24,44µm in B-blockers group, 291,23±21,34µm in ACEİ group, 290,44±26,72µm, 288,48±29,92µm, respectively. The decrease in SFCT was statistically significant in the beta-bloker group but not in the other groups.

Conclusions:

The results of this study demonstrated that SFCT decreases in patients with systemic arterial hypertension who used systemic B-blockers. This may be caused by arteriolar vascular contraction caused by blocking Beta receptors in the choroid.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy